Heparin Leader Hepalink Boasts over 420% Profit Growth

On July 13, 2024, Hepalink released preliminary results of the first half of 2024. According to the forecast, the company's net profit will be between 642 million yuan and 734 million yuan, a year-on-year increase of 420.70 percent to 495.72 percent. After excluding non-recurring gains and losses, the company's net profit is expected to be 308 million yuan to 401 million yuan, up 286.96 percent to 403.20 percent year-on-year.

As a leader in the field of Chinese heparin, Hepalink with high-value, for many years, has been in the field of heparin drug substances and drug products occupy a very important position. In the API sector,Hepalink has a global market share of nearly 40%, far outperforming its competitors. In the field of preparation, the company's main product enoxaparin sodium injection is also ranked in the forefront of the world, second only to the industry giant Sanofi.

Hepalink shares rose by the daily limit of 10% on July 15 on the news of the big increase. This also allows the outside world to further recognize the leading position of Hepalink in the global heparin market.

Behind the rapid growth of the industry analysis, Hepalink performance, on the one hand, thanks to the company for many years in the field of heparin's agriculture, have link of drug substances and drug products competitive advantage; In 2022 medical institutions, on the other hand, supplement of heparin inventory, to 2023 of the inventory, to a certain extent, also push up the growth of the company's performance.

Looking forward to the future, with the continuous increase in the demand for clinical drugs and the acceleration of the destocking process of downstream manufacturers, it is believed that Hepalink's position in the field of heparin will be further consolidated, and the performance growth is expected to continue.